Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) issued its quarterly earnings results on Thursday. The company reported $0.20 earnings per share for the quarter, topping the consensus estimate of $0.19 by $0.01, Zacks reports. Dr. Reddy's Laboratories had a net margin of 17.81% and a return on equity of 18.53%.
Dr. Reddy's Laboratories Stock Performance
RDY stock traded down $0.14 during midday trading on Friday, hitting $14.02. 1,781,386 shares of the stock traded hands, compared to its average volume of 2,268,659. The stock's fifty day simple moving average is $14.86 and its 200-day simple moving average is $15.52. The firm has a market cap of $11.70 billion, a P/E ratio of 22.39 and a beta of 0.51. Dr. Reddy's Laboratories has a 1-year low of $13.61 and a 1-year high of $16.89. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.92 and a quick ratio of 1.36.
Analyst Ratings Changes
A number of research analysts recently issued reports on the stock. Barclays decreased their target price on shares of Dr. Reddy's Laboratories from $17.40 to $17.00 and set an "overweight" rating for the company in a research report on Wednesday, November 6th. Nomura cut Dr. Reddy's Laboratories from a "buy" rating to a "neutral" rating in a report on Thursday, December 19th. Finally, StockNews.com lowered Dr. Reddy's Laboratories from a "buy" rating to a "hold" rating in a report on Friday, December 6th.
Read Our Latest Stock Analysis on Dr. Reddy's Laboratories
Dr. Reddy's Laboratories Company Profile
(
Get Free Report)
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.
Recommended Stories
Before you consider Dr. Reddy's Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dr. Reddy's Laboratories wasn't on the list.
While Dr. Reddy's Laboratories currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for February 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
